Author of the publication

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study, , , , , , , , , and 11 other author(s). Neuro Oncol, 20 (6): 826-837 (May 2018)Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, , , , , , , , , and 7 other author(s). Acta Neuropathol, 118 (4): 469-474 (October 2009)Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain, , , , , , , , , and 17 other author(s). Acta Neuropathol, (May 2015)ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma, , , , , , , , , and 9 other author(s). Acta Neuropathol, 129 (1): 133-146 (January 2015)Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations, , , , , , , , , and 46 other author(s). Acta Neuropathol, (March 2018)Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, , , , , , , , , and 17 other author(s). Acta Neuropathol, 130 (3): 407-417 (September 2015)N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma, , , , , , , , , and 9 other author(s). Neuro Oncol, (October 2018)Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets, , , , , , , , , and 18 other author(s). Acta Neuropathol, 131 (6): 903-910 (June 2016)N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma, , , , , , , , , and 9 other author(s). Neuro Oncol, 21 (1): 95-105 (January 2019)PARVMEC: An Efficient, Scalable Implementation of the Variational Moments Equilibrium Code., , , , , and . ICPP, page 618-627. IEEE Computer Society, (2016)